我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

替米沙坦改善原发性高血压病患者心肌肥厚及早期肾功能失调(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2005年第1期
页码:
39-41
栏目:
临床研究
出版日期:
2005-01-05

文章信息/Info

Title:
Effect of Telmisartan on left ventricular hypertrophy and earlier period renal dysfunction in patients with essential hypertension
作者:
于海波1; 韩雅玲2; 高柏青3; 佟铭2; 张新娅2; 王祖禄2; 许凤芝2
1.第四军医大学西京医院心血管内科,陕西 西安710032；沈阳军区总医院：2.心血管内科, 3.干诊科, 辽宁 沈阳110016
Author(s):
YU Haibo1;  HAN Yaling2;  GAO Baiqing3;  TONG Ming2;  ZHANG Xinya2; WANG Zulu2;  XU Fengzhi2
1.Department of Cardiology,Xijing Hospital,Fourth Military Medical University,Xi'an,Shaanxi 710032，China; 2.Department of Cardiology; 3.Department of Geriatrics, General Hospital of Shenyang Command of PLA, Shenyang, Liaoning 110016,China
关键词:
高血压; 替米沙坦; 心肌肥厚
Keywords:
hypertension;  telmisartan;  left ventricular hypertrophy
分类号:
R541.3; R972.4
DOI:
-
文献标识码:
A
摘要:
目的 评估替米沙坦在高血压病靶器官损害中的保护作用。方法 轻中度原发性高血压病左室肥厚患者60例服用替米沙坦40～80 mg/d，共26周，服药前后行超声心动图,观察舒张末期室间隔厚度（IVST），舒张末期左心室后壁厚度（LVPWT）及A/E比值的变化；并计算左室心肌质量指数（LVMI）的改变;同时放射免疫分析法测量血β2微球蛋白(β2MG)、尿β2MG含量。结果 替米沙坦能有效降低血压，降压有效率为72%，治疗后LVMI降低（146±12 vs 123±10）(P<0.01）,A/E值改善(P<0.05）,血、尿β2MG水平降低。结论 替米沙坦在降低血压同时能够有效地保护心肾功能。
Abstract:
AIM To evaluate the effect of Telmisartan on target organ damage in patients with mild to moderate hypertension. METHODS 60 patients with mild to moderate hypertension complicated with left ventricular hypertrophy were treated with Telmisartan for 26 weeks. The IVST，LVPWT，A/E，LVMI were checked by echocardiography and the concentrations of serum β2MG and urine β2MG were determined before and after treatment. RESULTS Both SBP and DBP decreased after the treatment of Telmisartan ,the effective rates were 72%, LVMI，A/E，serum β2MG and urine β2MG significantly decreased after Telmisartan treatment. CONCLUSION Telmisartan was effective not only in treating of hypertension but also in preventing heart and kidney from dysfunction.

参考文献/References

［1］ Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man .automatic validation of the method［J］. Circulation, 1977, 55:613-618.

［2］方志高. 替米沙坦治疗充血性心力衰竭的临床观察［J］. 心脏杂志, 2004, 16(4):342-343.

［3］Michel MC, Bohner H, Koster J, et al. Safety of telmisartan in patients with arterial hypertension : an open-label observational study［J］. Drug Saf, 2004, 27(5):335-344.

［4］于力，裴兆辉. 血管紧张素II受体拮抗剂在心血管疾病中的临床应用［J］. 心脏杂志，2002, 14（3）:266-267.

［5］英俊岐,王歆月,濮蓉晖. 高血压左室肥厚形成及其逆转研究进展［J］. 医学综述, 2003, 9(12):136-138.

［6］Mandarim-De-Lacerda CA, Pereira LM. Effect of telmisartan on preexistent cardiac and renal lesions in spontaneously hypertensive mature rats［J］. Histol Histopathol， 2004, 19(3):727-733.

［7］Ivanova OV, Fomicheva OA, Sergakova LM. Angiotensin II receptor blocker telmisartan: effect on 24-hour blood pressure profile and left ventricular hypertrophy in patients with hypertension ［J］. Kardiologiia, 2002, 42(2):45-49.

［8］Hernandez-Hernandez R, Sosa-Canache B, Velasco M, et al. Angiotensin II receptor antagonists role in arterial hypertension ［J］. Hypertens, 2002, 16（ Suppl 1）:S93-S99.

［9］徐瑞, 周聊生. 高血压病早期肾损害研究方法的进展［J］. 心血管病学进展, 2000,21(3):138-141.

［10］ Cupisti A, Rizza GM, D'Alessandro C ,et al. Effect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients［J］. Biomed Pharmacother， 2003, 57(3-4):169-172.

备注/Memo

备注/Memo:
收稿日期：2004-08-18.
更新日期/Last Update: 2010-01-05